Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTS824E)

• DTT Name: COVID-19 replicase polyprotein 1ab (pp1ab)
• Synonyms: ORF1ab polyprotein; pp1ab
• Gene Name: COVID-19 rep
• BioChemical Class: Coronaviruses polyprotein 1ab family
• UniProt ID: R1AB_SARS2
• TTD ID: T02107
• Function: Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein.
• Reactome Pathway:
  TRAF3-dependent IRF activation pathway (R-HSA-918233)
  Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC) (R-HSA-9694271)
  Maturation of replicase proteins (R-HSA-9694301)
  Translation of Replicase and Assembly of the Replication Transcription Complex (R-HSA-9694676)
  Replication of the SARS-CoV-2 genome (R-HSA-9694686)
  Transcription of SARS-CoV-2 sgRNAs (R-HSA-9694786)
  SARS-CoV-2 activates/modulates innate and adaptive immune responses (R-HSA-9705671)
  SARS-CoV-2 modulates host translation machinery (R-HSA-9754678)
  snRNP Assembly (R-HSA-191859)

Molecular Interaction Atlas (MIA) of This DTT

1 Drugs in Phase 3 Trial Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-441524	DMNZO7M	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3 Trial	[1]

References

• [1] Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128.